3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
28
NIH
16
INDUSTRY
3
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
1
Hematologic Neoplasms
1
Interventions
Radiotherapy
13
Cisplatin
8
Cytarabine
7
carfilzomib
5
Specimen Handling
5
Paclitaxel
5
Dexamethasone
5
Methotrexate
4
Lapatinib
4
Gemcitabine
4
Fluorouracil
4
Docetaxel
4
Brachytherapy
4
Biopsy
4
venetoclax
3
pomalidomide
3
Temozolomide
3
Radiotherapy, Conformal
3
Leucovorin
3
Irinotecan
3
Etoposide
3
Cyclophosphamide
3
Carboplatin
3
neratinib
2
merphos
2
Vincristine
2
Radiation
2
Polymerase Chain Reaction
2
Oxaliplatin
2
Immunohistochemistry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
NETWORK
×
Sirolimus
×
Clear all
NCT01460420
2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2
Completed
49 enrolled